信迪利珠单抗结合FOLFOX6化疗方案治疗进展期胃癌患者疗效分析

Sindilizumab combined with FOLFOX6 chemotherapy regimen analysis of efficacy in treating patients with advanced gastric cancer

目的 研究信迪利珠单抗结合FOLFOX6化疗方案对进展期胃癌患者免疫、血管新生及预后的影响,为改善胃癌患者预后提供参考。方法 选取2018年6月~2021年6月我院收治的120例进展期胃癌患者作为研究对象,以随机数字表法分为对照组和观察组,每组各60例。对照组采用FOLFOX6化疗方案,观察组在对照组基础上静滴信迪利珠单抗,均治疗3个周期。比较两组临床疗效、治疗前后免疫功能指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))、血管新生指标[碱性成纤维细胞因子(bFGF)、促血管生成素-2(Ang-2)、血管内皮生长因子(VEGF)、内皮抑素(ES)]、血清凋亡因子[B淋巴细胞瘤基因-2蛋白(Bcl-2)、B淋巴细胞瘤基因-2相关X蛋白(Bax)]水平及1年生存率。结果 观察组客观有效率(ORR)、疾病控制率(DCR)分别为60.00%、88.33%,均高于对照组(41.67%、68.33%),差异均有统计学意义(P<0.05)。治疗3个周期后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平降低幅度小于对照组;观察组血清Ang-2、VEGF、bFGF水平与对照组相比较低,ES水平较高;观察组血清Bcl-2水平低于对照组,Bax水平高于对照组,差异均有统计学意义(P<0.05)。观察组1年生存率90.91%高于对照组(75.44%),差异有统计学意义(P<0.05)。结论 信迪利珠单抗结合FOLFOX6化疗方案治疗进展期胃癌患者疗效肯定,可有效抑制肿瘤血管新生,改善免疫功能,提高患者1年生存率。

Objective To investigate the effects of sindilizumab combined with FOLFOX6 chemotherapy on immunity,neovascularisation and prognosis of patients with advanced gastric cancer,and to provide a reference for improving the prognosis of gastric cancer patients.Methods 120 cases of advanced gastric cancer patients admitted to our hospital from June 2018 to June 2021 were selected as research subjects,and were divided into a control group and an observation group by random number table method,with 60 cases in each group.The control group was treated with the FOLFOX6 chemotherapy program,while the observation group was treated with droplet Sindilizumab based on the control group for 3 cycles.Clinical efficacy,immune function indexes(CD3^(+),CD4^(+),CD4^(+)/CD8^(+)),angiogenesis indexes[basic fibroblast factor(bFGF),angiopoietin-2(Ang-2),vascular endothelial growth factor(VEGF),and endothelial suppressor(ES)],serum apoptotic factor[B lymphoblastoma gene-2 protein(Bcl-2),and B lymphoblastoma gene-2-related X protein(Bax)]levels,and the 1-year survival rates were compared between the two groups before and after treatment.Results The objective effective rate(ORR)and disease control rate(DCR)of the observation group were 60.00%and 88.33%,respectively,which were higher than those of the control group(41.67%and 68.33%),and the differences were statistically significant(P<0.05).After 3 cycles of treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group decreased less than those in the control group;the levels of serum Ang-2,VEGF and bFGF in the observation group were lower than those in the control group,while the levels of ES were higher;the levels of serum Bcl-2 in the observation group were lower than those in the control group,while the levels of Bax in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The 1-year survival rate of the observation group was 90.91%higher than that of the control group(75.44%),and the difference was statistically significant(P<0.05).Conclusion Sindilizumab combined with FOLFOX6 chemotherapy is effective in treating patients with advanced gastric cancer,which can effectively inhibit tumour neovascularization,improve immune function,and increase the 1-year survival rate of patients.